4-氯-6-(2-甲基-1H-咪唑并L-1-基)嘧啶 | 941294-31-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-氯-6-(2-甲基-1H-咪唑并L-1-基)嘧啶
• 中文别名: 4-氯-6-(2-甲基-1H-咪唑-1-基)嘧啶
• 英文名称: 4-Chloro-6-(2-methyl-1H-imidazol-1-yl)pyrimidine
• 英文别名: 4-chloro-6-(2-methylimidazol-1-yl)pyrimidine
• CAS: 941294-31-1
• 化学式: C₈H₇ClN₄
• 分子量: 194.623
• InChiKey: KTZYOMJEOTYZAX-UHFFFAOYSA-N

物化性质

• 沸点：
  392.5±52.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-氯-6-(2-甲基-1H-咪唑并L-1-基)嘧啶 、 2-(4-哌啶基)乙基]氨基磺酰胺盐酸盐 在 三乙胺 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 16.0h， 生成 4-(2-Methylimidazol-1-yl)-6-[4-[2-(sulfamoylamino)ethyl]piperidin-1-yl]pyrimidine
  参考文献：
  名称：

  Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: Alleviating hERG interactions through structure based design

  摘要：

  PC-1 (NPP-1) inhibitors may be useful as therapeutics for the treatment of CDDP (calcium pyrophosphate dehydrate) deposition disease and osteoarthritis. We have identified a series of potent quinazolin-4-piperidin-4-ethyl sulfamide PC-1 inhibitors. The series, however, suffers from high affinity binding to hERG potassium channels, which can cause drug-induced QT prolongation. We used a hERG homology model to identify potential key interactions between our compounds and hERG, and the information gained was used to design and prepare a series of quinazolin-4-piperidin-4-methyl sulfamides that retain PC-1 activity but lack binding affinity for hERG. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.006

文献信息

• Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: Alleviating hERG interactions through structure based design
  作者：Snahel D. Patel、Wendy M. Habeski、Alan C. Cheng、Elisa de la Cruz、Christine Loh、Natasha M. Kablaoui

  DOI：10.1016/j.bmcl.2009.04.006

  日期：2009.6

  PC-1 (NPP-1) inhibitors may be useful as therapeutics for the treatment of CDDP (calcium pyrophosphate dehydrate) deposition disease and osteoarthritis. We have identified a series of potent quinazolin-4-piperidin-4-ethyl sulfamide PC-1 inhibitors. The series, however, suffers from high affinity binding to hERG potassium channels, which can cause drug-induced QT prolongation. We used a hERG homology model to identify potential key interactions between our compounds and hERG, and the information gained was used to design and prepare a series of quinazolin-4-piperidin-4-methyl sulfamides that retain PC-1 activity but lack binding affinity for hERG. (C) 2009 Elsevier Ltd. All rights reserved.